Linda Yaccarino

On Fox Business with Tom Brady, she says eMed’s near-singular advantage is combining AI, technology and continuous clinical support so members stay on GLP-1 treatment, which she credits for 90% adherence and better health outcomes. A business claim about her company, not a general forecast. Her own turns in the YouTube auto-captions (01:26–03:10) inspected.

At a Milken Global Conference panel with Aon, she names two forces reshaping population health, new evidence on GLP-1 medications and AI-driven technology, and places eMed at the intersection of both. Her opening answer in the YouTube auto-captions (05:00–07:31) inspected; other panelists excluded.

At Semafor World Economy 2026, she says AI is at the core of eMed’s platform, one of the most empowering tools for clinicians and a powerful tool for patient transparency and education, giving access to information never available before. She agrees with her co-panelist that AI is the most powerful tool in healthcare today, while saying trusted spokespeople still matter. Asked about X, she cites the human, AI and technology resources she put into platform safety during her tenure, calls eight or nine months “several lifetimes in AI and tech” and declines to speak for X today. Her own turns in the YouTube auto-captions (09:58–17:00) inspected; the moderator’s and Zocdoc CEO’s words excluded.

Announcing eMed’s $200M raise, she calls GLP-1s one of the most powerful advances in medicine in human history, says they only work if people stay on them, and says eMed built an “empathic agentic AI platform” that guides members every step of the way. She describes the company as building the future of AI-powered population health. Company announcement; full post text inspected, comments excluded.

After speaking with Arianna Huffington at The Female Quotient’s AI Summit, she says her career has been about giving people tools and technology to improve their lives. GLP-1 medications paired with AI form more than a medical shift, letting eMed deliver personal, empathetic care at home and move from reactive care to prevention while bending both the health and cost curves. Full post text inspected, comments excluded.

Interviewed by Axios at Cannes Lions while still CEO of X, she says X has merged with the fastest-growing, smartest AI company, that Grok powers the timeline, content moderation and search, and that Grok differs from ChatGPT, Gemini, Claude and Llama because it alone trains on X’s real-time data. She credits Grok’s growth to the biggest data center in the world, says Grok 3.5 will be the smartest model in the world, and pitches it to marketers for trends, predictions and research. Executive sales messaging. Her own turns in the YouTube auto-captions (10:00–18:28) inspected; the interviewer’s questions excluded.

Speaking to Yahoo Finance at Cannes, she frames xAI’s acquisition of X as the most powerful AI company joining a media platform with unique real-time conversation data, and says that with X fueled so aggressively by AI, Grok-driven recommendation and moderation are now the advertiser’s north star. Executive messaging. Her own turns in the YouTube auto-captions (06:45–13:10) inspected; the interviewer’s framing excluded.

Older context. At an Axios event during Cannes Lions 2024, she calls Grok a newborn whose goal is to become the best truth-seeking AI assistant, with up-to-the-moment X data as its differentiator. Asked about licensing X data to other AI companies, she says business models come later and that a truth-seeking AI matters most for the world. Her own turns in the YouTube auto-captions (09:02–10:29, 19:50) inspected.

Older context. When X joined the voluntary Munich accord against AI election deepfakes, she said in a statement that every citizen and company must safeguard free and fair elections and that X would collaborate with peers against AI threats while protecting free speech and maximizing transparency. A corporate statement, quoted by the Associated Press; her only found remark on AI harms. Article text with her direct quotes inspected.